ÑÇÐÇÓÎÏ·¹ÙÍø-www.yaxin868.com

ɽ¶«ÑÇÐÇÓÎÏ·¹ÙÍø»ú´²ÓÐÏÞ¹«Ë¾Ï³´²¹Ù·½ÍøÕ¾½ñÌìÊÇ£º2025-04-18Çл»³ÇÊÐ[È«¹ú]-ÍøÕ¾µØÍ¼
ÍÆ¼ö²úÆ· :
ÍÆ¼öÐÂÎÅ
¼¼ÊõÎÄÕµ±Ç°Î»ÖÃ:¼¼ÊõÎÄÕÂ>

¼ì²âGalectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐµÄÖÆ×÷·½·¨

ʱ¼ä:2025-04-17    ×÷Õß: ¹ÜÀíÔ±

רÀûÃû³Æ£º¼ì²âGalectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐµÄÖÆ×÷·½·¨
¼¼ÊõÁìÓò£º
±¾·¢Ã÷ÊôÓÚҽѧÉúÎï¼¼ÊõÁìÓò£¬Éæ¼°Ò»ÖÖʱ¼ä·Ö±æÃâÒßÓ«¹â(Time Resolved Fluoroimmunoassay, TRF)¼ì²â·½·¨£¬¾ßÌåΪӦÓÃʱ¼ä·Ö±æÃâÒßÓ«¹â·½·¨¼ì²âÑùÆ·ÖÐµÄ Galectin-3µ°°×µÄŨ¶È¡£ÈËÍâÖÜѪÖÐ(ialectin-3µ°°×Ũ¶ÈµÄÔö¼ÓÓëÒÈÏÙ°©µÄ·¢Éú·¢Õ¹´æÔÚÃÜÇйØÁª£¬ÔËÓñ¾ÊÔ¼ÁºÐÄܹ»¶ÔÒÈÏÙ°©µÄ·¢Éú·¢Õ¹Æðµ½Õï¶Ï×÷Óá£
±³¾°¼¼Êõ£º
(ialectin-3ÊǦ -°ëÈéÌÇÜÕ½áºÏµ°°×£¬Êôlectin¼Ò×å³ÉÔ±£¬Ëü¾ßÓÐCRD½á¹¹Óò£¬ Ó뺬¦Â-°ëÈéÌÇÜÕµÄÌǵ°°×ºÍÌÇÖ¬¾ßÓкܸߵÄÇ׺ÍÁ¦£¬ÔÚϸ°ûÓëϸ°û¡¢Ï¸°ûÓë»ùÖÊÖ®¼äÆðµ½ÌØÒìÐÔÕ³¸½×÷Óã¬ÓëÖ×ÁöµÄ×ªÒÆ¡¢½þÈó¡¢Éú³¤ºÍÕ³¸½ÃÜÇÐÏà¹Ø¡£ÎÒÃÇÔËÓÃMALDI-T0F-MSÖÊÆ×¼¼Êõ·¢ÏÖ(ialectin-3ÔÚÈËÒÈÏÙ°©×éÖ¯ÖгÊÏָ߱í´ï[1]£¬²¢ÇÒËüµÄ±í´ïˮƽÓëÒÈÏÙ°©µÄ·ÖÆÚ¼°Ô¤ºóÏà¹Ø¡£ÎÒÃǵÄÑо¿·¢ÏÖ£¬Õý³£ÈË¡¢ÒÈÏÙ°©ºÍÆäËüÏû»¯ÏµÍ³Ö×ÁöÍâÖÜѪÇåÖоùδ¼ì²â³öfeilectin-3µ°°×£¬¶øÒÈÏÙ°©»¼ÕßÍâÖÜѪÇåÖеÄfeilectin-3ÑôÐÔÂʸߴïΪ30% ¦Â]¡£Òò´Ë£¬Galectin-3¶ÔÒÈÏÙ°©¾ßÓÐÃ÷È·µÄÕï¶Ï¼ÛÖµ¡£Ê±¼ä·Ö±æÃâÒßÓ«¹â(Time Resolved Fluoroimmunoassay, TRF)¼ì²â·½·¨ÊÇÒ»ÖÖ³ÉÊìµÄÃâÒß·ÖÎö·½·¨£¬¾ßÓиßÌØÒì¡¢¸ßÁéÃôµÄÓŵ㣬ÊÇÔÚÁÙ´²Ò½Ñ§ºÍ¼ìÑéҽѧµÈÖî¶à·½ÃæµÃµ½Ê®·Ö¹ã·ºµÄÓ¦Óã¬ÊÇĿǰȡ´ú·ÅÉäÐÔÃâÒß·ÖÎöµÄÒ»ÖÖ¶¨Á¿¼ì²â·½·¨¡£ËüµÄ»ù±¾Ô­ÀíÊÇÀûÓÃÈý¼ÛÏ¡ÍÁÀë×Ó(ÈçEu3+)×÷Ϊʾ×ÙÎÑÓ³Ù¼ì²âÊÙÃü½Ï³¤µÄÌØÒìÐÔ¼¤·¢Ó«¹âÒÔÅųý·ÇÌØÒìÐÔ¼°±³¾°Ó«¹âµÄ¸ÉÈÅ£¬¼´²â¶¨¸´ºÏÎïÖеÄÏ¡ÍÁÀë×Ó±»¼¤·¢µÄÑÓ³ÙÓ«¹âÇ¿¶È£¬´Ó¶øÈ·¶¨´ý²âµ°°×µÄŨ¶È¡£Ê¹ÓÃÓ«¹âÔöǿҺµÄTRFÄܹ»¼ì²âµ½Æ¤¿Ë(pg£¬10 ¡ª 12g/ml)ˮƽµÄµ°°×£¬Òò´Ë£¬ ±¾ÊÔ¼ÁºÐ²ÉÓÃTRFµÄ·½·¨À´¼ì²â(ialectin-3µÄŨ¶È£¬ÊÇ¿¼ÂÇÁË¶à·½ÃæµÄÓŵ㡣Ŀǰ£¬¹ú¼ÊÉÏ»¹Ã»Óб¨µÀרÃÅÓÃÓÚ¼ì²â(ialectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹â·½·¨£¬Ò²Ã»ÓÐÏàÓ¦µÄÊÔ¼ÁºÐÌṩ£¬Òò´Ë£¬¸ÃÊÔ¼ÁºÐµÄ¿ª·¢ºÍÓ¦Óã¬ÊÇÌî²¹ÁËÕâ·½ÃæµÄ¿Õ°×¡£²Î¿¼ÎÄÏ×
1.Jian-Hua Chen, Run-Zhou Ni ¡î , Ming-Bing Xiao, et al. Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int. 2009 Apr;8(2):193-200. (¡î :Corresponding author)
2.¸ð·É£¬ÄßÈóÖޡФÃ÷±ø£¬½­·ã£¬Â½´ä»ª£¬ÀîÁ¢ÈË£¬Öì¾»£¬ÀîСÑ壬ÁõÕØÐÞ¡£ÑªÇå (ialectin-3¶ÔÒÈÏÙ°©Õï¶Ï¼ÛÖµµÄ³õ̽¡£¡¶ÄÏͨ´óѧѧ±¨(ҽѧ°æ)¡·£¬2010,30 (1):32 ¡ª 3
·¢Ã÷ÄÚÈÝ
±¾·¢Ã÷µÄÄ¿µÄÊÇÌṩһÖÖÁéÃô¡¢ÌØÒìµÄ¼ì²âÑù±¾ÖÐ(ialectin-3µ°°×Ũ¶ÈµÄÊÔ¼ÁºÐ¼°ÆäÖÆ±¸·½·¨¡£±¾·¢Ã÷µÄÄ¿µÄÊÇͨ¹ýÒÔÏ·½·¨ÊµÏÖµÄÔÚø±ê°åÖÐÓðü±»¿¹Ìå(µ¥¿Ë¡СÊó¿¹ÈËGalectin-3¿¹Ìå)°ü±»£¬·â±Õºó¼ÓÈë´ý²âÑùÆ··õÓý£¬Ï´°å£¬¼ÓÈë¼ì²â¿¹Ìå(ÉúÎïËØ»¯µÄÑò¿¹ÈË (ialectin-3¶à¿¹)·õÓý£¬ÔÙ´ÎÏ´°åºó¼ÓÈëEu3 +±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ·õÓý£¬È»ºóÏ´°å¼ÓÈëÓ«¹âÔöǿҺ£¬Õñµ´5·ÖÖÓºóÓÃ337nm²¨³¤¹â¼¤·¢£¬ÑÓʱ200΢ÃëÔÚ615nm²¨³¤´¦¼ì²â·¢ÉäÓ«¹âÖµ£» ͨ¹ý±ê׼ƷµÄŨ¶ÈºÍÏàÓ¦µÄÓ«¹âÖµ»æÖƱê×¼ÇúÏߣ¬´ý¼ìÑùÆ·ÖеÄ(ialectin-3Ũ¶È¾Í¿ÉÒÔͨ¹ýËüµÄÓ«¹âÖµ²¢¶ÔÓ¦±ê×¼ÇúÏߵõ½¡£±¾·¢Ã÷¼ì²â(ialectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐ£¬Æä°üÀ¨ÒÔÏÂ×é³É
(1)°ü±»»º³åҺΪÁ×ËáÑλº³åÒº(PBS)£¬Æä³É·ÖΪ140mMNaCl, 2. 7mM KCl, IOmM Na2HPO4,1. 8mM KH2PO4, pH ֵΪ 7¡¤ 4 £»
(2)·â±ÕҺΪº¬1%BSAµÄPBS£¬Æä³É·ÖΪPBS£¬1%BSA£»
(3)Ï´µÓҺΪº¬0. 05%Tween-20 µÄ iTris-HCl »º³åÒº(TBS)£¬Æä³É·ÖΪ SOmMmiTris-HCl »º³åÒº(pH 7. 8),0. 05%Tween-20 £»
(4)¼ÓÑù»º³åÒºµÄ³É·ÖΪº¬1%BSAµÄPBS£¬Æä³É·ÖΪPBS£¬1%BSA£»
(5)Ó«¹âÔöǿҺ(EnhancementSolution)£»
(6)¼ì²â»º³åÒº(AssayBuffer)Ϊ50mMµÄTris-HCl»º³åÒº(pH 7.8)£¬ÆäÖк¬ÓÐ 1%BSA,l%bovine globulin,0. 05%Tween 40£¬DTPA £»
(7)°ü±»¿¹ÌåΪµ¥¿Ë¡СÊó¿¹ÈËfeilectin-3¿¹Ìå(MonoclonalAnti-Human Galectin-3 Antibody)£¬´¢´æÅ¨¶ÈΪ 1 ¦Ì g/ ¦Ì 1 £»
(8)¼ì²â¿¹ÌåΪÉúÎïËØ»¯µÄÑò¿¹ÈËfeilectin-3¶à¿¹(BiotinylatedAnti-Human Galectin-3 Antibody)£¬´¢´æÅ¨¶ÈΪ 50ng/ ¦Ì 1 £»
(9)Eu3+±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3+-labeled strÓ¡tavidin)£¬´¢´æÅ¨¶ÈΪ0. 1 ¦Ì g/ ¦Ì 1 £»
(10)±ê׼Ʒ£¬ÖØ×éÈËGalectin-3 µ°°×(Recombinant Human Galectin-3)£¬Å¨¶ÈΪ 100 ¦Ì g/¦Ì 1¡£
±¾·¢Ã÷¼ì²âfelectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐµÄʹÓò½ÖèÈçÏÂ
(1)ÓÃPBSÏ¡ÊͰü±»¿¹ÌåÒ»µ¥¿Ë¡СÊó¿¹ÈËfeilectin-3¿¹Ìå(MonoclonalAnti-Human Galectin-3 Antibody)ÖÁŨ¶ÈΪ4¦Ì g/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈë96¿×ø±ê°å£¬4¡ãC¹ýÒ¹£»
(2)ÆúÈ¥°ü±»¿¹Ì壬300¦Ì1/¿×Ï´µÓҺϴµÓÈý´Î£¬¼ÓÈë·â±ÕÒº200¦Ì 1/¿×£¬37¡ãC·õÓýIh £»
(3)ÆúÈ¥·â±ÕÒº£¬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£¬¼ÓÈë´ý²âÅàÑøÉÏÇåÑùÆ·ºÍ±¶±ÈÏ¡Ê͵ıê׼Ʒ100¦Ì 1/¿×£¬37¡ãC·õÓýIh £»
(4)ÆúÈ¥ÑùÆ·ºÍ±ê׼Ʒ£¬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£»
(5)ÓüÓÑù»º³åҺϡÊͼì²â¿¹ÌåÒ»ÉúÎïËØ»¯µÄÑò¿¹ÈË(ialectin-3¶à¿¹(Biotinylated Anti-Human Galectin-3 Antibody)ÖÁŨ¶ÈΪ75ng/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈëÏ¡Êͺõļì²â¿¹Ì壬37¡ãC·õÓýlh£»
(6)ÆúÈ¥¼ì²â¿¹Ì壬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£»
(7)Óüì²â»º³åÒº(AssayBuffer)Ï¡ÊÍEu3 +±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3 +-labeled strÓ¡tavidin)£¬ÖÕŨ¶ÈΪ500ng/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈëø±ê°å£¬37¡ãC±Ü¹â·õÓýIh £»
(8)ÆúÈ¥Eu3+±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3+-labeled strÓ¡tavidin)£¬300 ¦Ì 1/¿×Ï´µÓҺϴµÓËÄ´Î
(9)¼ÓÈëÓ«¹âÔöǿҺ(EnhancementSolution) 200 ¦Ì 1/¿×£¬ÊÒαܹ⻺Âýˮƽҡ¶¯5min £»
(10)¶Á°åÉ趨¼¤·¢¹â²¨³¤(Excitationwavelength)Ϊ337nm£¬·¢Éä¹â²¨³¤ (Emission wavelength)Ϊ615nm£¬ÑÓʱ200΢Ãë²â¶¨615nm´¦µÄÓ«¹âÖµ£»
(11)ÀûÓÃͳ¼ÆÑ§»æÍ¼Èí¼þ¸ù¾Ý²â¶¨µÄÖµ»æÖƱê×¼ÇúÏߣ»
(12)ͨ¹ý±ê×¼ÇúÏߺÍδ֪Ũ¶ÈÑùÆ·µÄÓ«¹âÖµ¼ÆËã´ý²âÑùÆ·ÖеÄ(ialectin-3µÄŨ¶È¡£
±¾ÊÔ¼ÁºÐ²ÉÓÃʱ¼ä·Ö±æÃâÒßÓ«¹â·½·¨À´¼ì²âÑùÆ·ÖеÄfelectin-3µ°°×Ũ¶È£¬ÆäÖÐÓ¦ÓÃÁËË«¿¹Ìå¼ÐÐÄ·¨£¬ÀûÓðü±»¿¹ÌåÒ»µ¥¿Ë¡СÊó¿¹ÈËfeilectin-3¿¹Ìå(Monoclonal Anti-Human Galectin-3 Antibody)À´²¶»ñÑùÆ·ÖÐ΢Á¿µÄfeilectin-3µ°°×£¬È»ºóÓÃÉúÎïËØ it^i^-iKA Galectin-3 (Biotinylated Anti-Human Galectin-3 Antibody) ²¶»ñµÄ(ialectin-3µ°°×½áºÏ£¬ÓÉÓÚÉúÎïËØÓëÁ´Ç׺ÍÃ¹ËØÄܹ»¸ßÇ׺ÍÁ¦½áºÏ£¬ÎÒÃÇÓÃEu3+±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3 + -labeled streptavidin)À´ÓëÉúÎïËØ»¯µÄÑò¿¹ÈËfeilectin-3¶à¿¹½áºÏ£¬ÐγÉÈýÃ÷ÖÎÑù¸´ºÏ½á¹¹£¬ÑùÆ·ÖеÄ(ialectin-3¾Í±»Eu3+±ê¼ÇÉϲ¢¹Ì¶¨ÔÚø±ê°åÖУ¬ ×îºóÓ¦ÓÃ337nm²¨³¤µÄ¼¤·¢¹â¼¤·¢£¬ÔÚ·¢Éä¹â²¨³¤(Emission wavelength)Ϊ615nm´¦£¬²â¶¨Ó«¹âÖµ£»È»ºó¸ù¾Ý±ê×¼ÇúÏßÀ´¼ÆËã(Galectin-3µÄŨ¶È¡£Ó¦ÓÃʱ¼ä·Ö±æÃâÒßÓ«¹â·¨À´¸ßÁéÃô¡¢¸ßÌØÒìµØ¼ì²âÍâÖÜѪÖеÄfelectin-3Ũ¶ÈÊǸÃÊÔ¼ÁºÐµÄÒ»¸ö×îÏÔÖøÌØÉ«ºÍ´´Ð¡£
±¾·¢Ã÷»¹¾ßÓÐÁ¼ºÃµÄÎȶ¨ÐÔ£¬²Ù×÷ʱ¼ä¶Ì£¬³É±¾µÍ¡£


ͼ1Ϊ¼ì²â(ialectin-3µ°°×Ũ¶ÈµÄ¼ì²â±ê×¼ÇúÏß¡£
¾ßÌåʵʩÀý·½Ê½±¾·¢Ã÷ÖеÄһЩÊõÓïÓëËõдTRF:ʱ¼ä·Ö±æÃâÒßÓ«¹â£»BSA:ţѪÇå°×µ°°×£» Tween-20 ÍÂÎÂ20 £»Tween-40 ÍÂÎÂ40 £»PBS Á×ËáÑλº³åÒº£»TBS =Tris-HCl »º³åÒº£»bovine globulin Å£Çòµ°°×£»DTPA ¶þÒÒÏ©Èý°·ÎåÒÒËá¡£ÊÔ¼ÁÅä·½
1.»º³åÒº
°ü±»»º³åҺΪÁ×ËáÑλº³åÒº(PBS)£¬Æä³É·ÖΪ140mM NaCl,2. 7mM KCl, IOmM Na2HPO4, 1. 8mM KH2PO4, pH ֵΪ 7¡¤ 4 £»
Ï´µÓҺΪº¬0. 05%Tween-20µÄiTris-HCl»º³åÒº(TBS)£¬Æä³É·ÖΪ50mMµÄiTris-HCl »º³åÒº(pH 7. 8),0. 05%Tween-20 £»
·â±ÕҺΪº¬1%BSAµÄPBS£¬Æä³É·ÖΪPBS£¬1%BSA £» ¼ÓÑù»º³åҺΪº¬1%BSAµÄPBS£¬Æä³É·ÖΪPBS£¬1%BSA £»
¼ì²â»º³åҺΪ50mMµÄTris-HCl»º³åÒº(pH 7. 8)£¬ÆäÖк¬ÓÐ1%BSA, l%bovine globulin,0. 05%Tween 40£¬DTPA £»
2.±ê׼Ʒµ°°×
ÉÌÆ·»¯µÄÖØ×éÈËfeilectin-3µ°°×(R&D¹«Ë¾²úÆ·)4.ø±ê°å
Nunc°ËÁª¿×ø±êÌõ
±¾·¢Ã÷ÔËÓÃʱ¼ä·Ö±æÃâÒßÓ«¹â·½·¨À´¼ì²âÑùÆ·ÖеÄfelectin-3µ°°×Ũ¶È£¬ÆäÊÔ¼ÁºÐµÄʹÓò½ÖèÈçÏÂ
(1)ÓÃPBSÏ¡ÊͰü±»¿¹ÌåÒ»µ¥¿Ë¡СÊó¿¹ÈËfeilectin-3¿¹Ìå(MonoclonalAnti-Human Galectin-3 Antibody)ÖÁŨ¶ÈΪ4¦Ì g/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈë96¿×ø±ê°å£¬4¡ãC¹ýÒ¹£»
(2)ÆúÈ¥°ü±»¿¹Ì壬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£¬¼ÓÈë·â±ÕÒº200 ¦Ì 1/¿×£¬37¡ãC·õÓýIh £»
(3)ÆúÈ¥·â±ÕÒº£¬300¦Ì1/¿×Ï´µÓҺϴµÓÈý´Î£¬¼ÓÈë´ý²âÅàÑøÉÏÇåÑùÆ·ºÍ±¶±ÈÏ¡Ê͵ıê׼Ʒ100¦Ì 1/¿×£¬37¡ãC·õÓýIh £»
(4)ÆúÈ¥ÑùÆ·ºÍ±ê׼Ʒ£¬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£»
(5)ÓüÓÑù»º³åҺϡÊͼì²â¿¹ÌåÒ»ÉúÎïËØ»¯µÄÑò¿¹ÈË(ialectin-3¶à¿¹(Biotinylated Anti-Human Galectin-3 Antibody)ÖÁŨ¶ÈΪ75ng/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈëÏ¡Êͺõļì²â¿¹Ì壬37¡ãC·õÓýlh£»
(6)ÆúÈ¥¼ì²â¿¹Ì壬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£»
(7)Óüì²â»º³åÒº(AssayBuffer)Ï¡ÊÍEu3 +±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3 +-labeled strÓ¡tavidin)£¬ÖÕŨ¶ÈΪ500ng/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈëø±ê°å£¬37¡ãC±Ü¹â·õÓýIh £»
(8)ÆúÈ¥Eu3+±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3+-labeled strÓ¡tavidin)£¬300 ¦Ì 1/¿×Ï´µÓҺϴµÓËÄ´Î
(9)¼ÓÈëÓ«¹âÔöǿҺ(EnhancementSolution) 200 ¦Ì 1/¿×£¬ÊÒαܹ⻺Âýˮƽҡ¶¯ 5min £»
(10)¶Á°åÉ趨¼¤·¢¹â²¨³¤(Excitationwavelength)Ϊ337nm£¬·¢Éä¹â²¨³¤ (Emission wavelength)Ϊ615nm£¬ÑÓʱ200΢Ãë²â¶¨615nm´¦µÄÓ«¹âÖµ£»
(11)ÀûÓÃͳ¼ÆÑ§»æÍ¼Èí¼þ¸ù¾Ý²â¶¨µÄÖµ»æÖƱê×¼ÇúÏߣ»
(12)ͨ¹ý±ê×¼ÇúÏߺÍδ֪Ũ¶ÈÑùÆ·µÄÓ«¹âÖµ¼ÆËã´ý²âÑùÆ·ÖеÄ(ialectin-3µÄŨ¶È¡£
ȨÀûÒªÇó
1.¼ì²âfeilectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐ£¬ÆäÌØÕ÷ÔÚÓÚ°üÀ¨ÒÔÏÂ×é³É(1)°ü±»»º³åҺΪÁ×ËáÑλº³åÒº(PBS)£¬Æä³É·ÖΪ140mMNaCl, 2. 7mM KCl, IOmM Na2HPO4,1. 8mM KH2PO4, pH ֵΪ 7¡¤ 4 £»(2)·â±ÕҺΪº¬1%BSAµÄPBS£¬Æä³É·ÖΪPBS£¬1%BSA£»(3)Ï´µÓҺΪº¬0. 05%Tween-20 µÄ iTris-HCl »º³åÒº(TBS)£¬Æä³É·ÖΪ 50mM µÄ iTris-HCl »º³åÒº(pH 7. 8),0. 05%Tween-20 £»(4)¼ÓÑù»º³åÒºµÄ³É·ÖΪº¬1%BSAµÄPBS£¬Æä³É·ÖΪPBS£¬1%BSA£»(5)Ó«¹âÔöǿҺ(EnhancementSolution)£»(6)¼ì²â»º³åÒº(AssayBuffer)Ϊ50mMµÄTris-HCl»º³åÒº(pH 7.8)£¬ÆäÖк¬ÓÐ 1%BSA,l%bovine globulin,0. 05%Tween 40£¬DTPA £»(7)°ü±»¿¹ÌåΪµ¥¿Ë¡СÊó¿¹ÈËfeilectin-3¿¹Ìå(MonoclonalAnti-Human Galectin-3 Antibody)£¬´¢´æÅ¨¶ÈΪ 1 ¦Ì g/ ¦Ì 1 £»(8)¼ì²â¿¹ÌåΪÉúÎïËØ»¯µÄÑò¿¹ÈËfeilectin-3¶à¿¹(BiotinylatedAnti-Human Galectin-3 Antibody)£¬´¢´æÅ¨¶ÈΪ 50ng/ ¦Ì 1 £»(9)Eu3+±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3+-labeled strÓ¡tavidin)£¬´¢´æÅ¨¶ÈΪ0. 1 ¦Ì g/ ¦Ì 1 £»(10)±ê׼Ʒ£¬ÖØ×éÈËGalectin-3 µ°°×(Recombinant Human Galectin-3)£¬Å¨¶ÈΪ 100 ¦Ì g/¦Ì 1¡£
2.ÈçȨÀûÒªÇó1ËùÊö¼ì²âfelectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐµÄʹÓ÷½·¨£¬ÆäÌØÕ÷ÔÚÓÚÒÔϲ½Öè(1)ÓÃPBSÏ¡ÊͰü±»¿¹ÌåÒ»µ¥¿Ë¡СÊó¿¹ÈËfeilectin-3¿¹Ìå(MonoclonalAnti-Human Galectin-3 Antibody)ÖÁŨ¶ÈΪ4¦Ì g/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈë96¿×ø±ê°å£¬4¡ãC¹ýÒ¹£»(2)ÆúÈ¥°ü±»¿¹Ì壬300¦Ì1/¿×Ï´µÓҺϴµÓÈý´Î£¬¼ÓÈë·â±ÕÒº200¦Ì 1/¿×£¬37¡ãC·õÓýIh £»(3)ÆúÈ¥·â±ÕÒº£¬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£¬¼ÓÈë´ý²âÅàÑøÉÏÇåÑùÆ·ºÍ±¶±ÈÏ¡Ê͵ıê׼Ʒ100¦Ì 1/¿×£¬37¡ãC·õÓýIh £»(4)ÆúÈ¥ÑùÆ·ºÍ±ê׼Ʒ£¬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£»(5)ÓüÓÑù»º³åҺϡÊͼì²â¿¹ÌåÒ»ÉúÎïËØ»¯µÄÑò¿¹ÈË(ialectin-3¶à¿¹(Biotinylated Anti-Human Galectin-3 Antibody)ÖÁŨ¶ÈΪ75ng/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈëÏ¡Êͺõļì²â¿¹Ì壬37¡ãC·õÓýlh£»(6)ÆúÈ¥¼ì²â¿¹Ì壬300¦Ì 1/¿×Ï´µÓҺϴµÓÈý´Î£»(7)Óüì²â»º³åÒº(AssayBuffer)Ï¡ÊÍEu3 +±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3 +-labeled strÓ¡tavidin)£¬ÖÕŨ¶ÈΪ500ng/ml£¬ÒÔ100 ¦Ì 1/¿×¼ÓÈëø±ê°å£¬37¡ãC±Ü¹â·õÓýIh £»(8)ÆúÈ¥Eu3+±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ(Eu3+-labeled strÓ¡tavidin)£¬300 ¦Ì 1/¿×Ï´µÓҺϴµÓËÄ´Î(9)¼ÓÈëÓ«¹âÔöǿҺ(EnhancementSolution) 200 ¦Ì 1/¿×£¬ÊÒαܹ⻺Âýˮƽҡ¶¯ 5min £»(10)¶Á°åÉ趨¼¤·¢¹â²¨³¤(Excitationwavelength)Ϊ337nm£¬·¢Éä¹â²¨³¤ (Emission wavelength)Ϊ615nm£¬ÑÓʱ200΢Ãë²â¶¨615nm´¦µÄÓ«¹âÖµ£»(11)ÀûÓÃͳ¼ÆÑ§»æÍ¼Èí¼þ¸ù¾Ý²â¶¨µÄÖµ»æÖƱê×¼ÇúÏߣ»(12)ͨ¹ý±ê×¼ÇúÏߺÍδ֪Ũ¶ÈÑùÆ·µÄÓ«¹âÖµ¼ÆËã´ý²âÑùÆ·ÖеÄ(ialectin-3µÄŨ¶È¡£
È«ÎÄÕªÒª
¼ì²âGalectin-3µÄʱ¼ä·Ö±æÃâÒßÓ«¹âÊÔ¼ÁºÐ¡£ÊÔ¼ÁºÐ°üÀ¨°ü±»»º³åÒº£»·â±ÕÒº£»Ï´µÓÒº£»¼ÓÑù»º³åÒº£»Ó«¹âÔöǿҺ£»¼ì²â»º³åÒº£»°ü±»¿¹Ìå(µ¥¿Ë¡СÊó¿¹ÈËGalectin-3¿¹Ìå)£»¼ì²â¿¹Ìå(ÉúÎïËØ»¯µÄÑò¿¹ÈËGalectin-3¶à¿¹)£»Eu3£«±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ£»±ê׼Ʒ(ÖØ×éÈËGalectin-3µ°°×)¡£ÆäʹÓðüÀ¨¸ÃÊÔ¼ÁºÐ²ÉÓÃË«¿¹Ìå¼ÐÐÄ·¨ºÍʱ¼ä·Ö±æÃâÒßÓ«¹âÔ­ÀíÀ´¼ì²âÑùÆ·ÖеÄGalectin-3µ°°×µÄŨ¶È¡£ÔÚø±ê°åÖаü±»¿¹Ìå°ü±»£¬·â±Õºó¼ÓÈë´ý²âÑùÆ··õÓý£¬Ï´°å£¬¼ÓÈë¼ì²â¿¹Ìå·õÓý£¬ÔÙ´ÎÏ´°åºó¼ÓÈëEu3£«±ê¼ÇµÄÁ´Ç׺ÍÃ¹ËØ·õÓý£¬È»ºóÏ´°å¼ÓÈëÓ«¹âÔöǿҺ£¬Õñµ´5·ÖÖÓºóÓÃ337nm²¨³¤¹â¼¤·¢£¬ÑÓʱ200΢ÃëÔÚ615nm²¨³¤´¦¼ì²â·¢ÉäÓ«¹âÖµ£»Í¨¹ý±ê׼ƷµÄŨ¶ÈºÍÏàÓ¦µÄÓ«¹âÖµ»æÖƱê×¼ÇúÏߣ¬´ý¼ìÑùÆ·ÖеÄGalectin-3Ũ¶È¾Í¿ÉÒÔͨ¹ýËüµÄÓ«¹âÖµ²¢¶ÔÓ¦±ê×¼ÇúÏߵõ½¡£
Îĵµ±àºÅG01N33/577GK102226809SQ201110036899
¹«¿ªÈÕ2011Äê10ÔÂ26ÈÕ ÉêÇëÈÕÆÚ2011Äê2ÔÂ13ÈÕ ÓÅÏÈȨÈÕ2011Äê2ÔÂ13ÈÕ
·¢Ã÷ÕßÄßÈóÖÞ, Äßο®, ФÃ÷±ø ÉêÇëÈË:ÄßÈóÖÞ, Äßο®, ФÃ÷±ø

  • רÀûÃû³Æ£ºÒ»ÖÖ»ý·ÖÇòµÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÊôÓÚ¹â·øÉä²âÁ¿ÁìÓò£¬¾ßÌåÉæ¼°Ò»ÖÖ»ý·ÖÇò¡£±³¾°¼¼Êõ£º»ý·ÖÇòÓÖ³ÆÎª¹âͨÇò£¬ÊÇÒ»¸öÖпյģ¬ÄÚ±ÚͿһ²ãƽÕûµÄÂþ·´Éä²ÄÁϵÄÍêÕûÇò¿Ç£¬ÆäµäÐ͵ŦÄܾÍÊÇÊÕ¼¯¹â£¬ÊÕ¼¯µÄ¹â±»ÓÃ×÷Ò»¸öÉ¢Éä¹âÔ´»ò×÷Ϊ²âÁ¿Óã¬ÒòÆä
  • רÀûÃû³Æ£ºÒ»ÖÖ¸Ö¹Ü×Ô¶¯Í¨¾¶»úµÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷ÊôÓÚ½ðÊô¹ÜµÀÉú²úÉ豸ÁìÓò£¬ÌرðÉæ¼°Ò»ÖÖ¸Ö¹Ü×Ô¶¯Í¨¾¶»ú¡£±³¾°¼¼Êõ£º½ðÊô¹ÜµÀ¾­³ÉÐÍ¡¢º¸½Ó¡¢Çжϼӹ¤Íê³Éºó£¬ÐèÒª½øÐÐͨ¾¶¼ì²â£¬¼ì²é¹ÜµÀÄÚ¾¶ÊÇ·ñ·ûºÏ±ê×¼£¬ÓÐÎÞ͹Àâ¡¢ÄÚÏÝ¡¢°¼±ñµÈÓ°ÏìÄÚ¾¶µÄȱÏÝ¡£ÒÔ
  • רÀûÃû³Æ£ºÖÐ×ÓÖ¯¹¹²âÊÔÉ豸µÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°ÖÐ×Ó·øÉä¼¼ÊõÁìÓò£¬ÓÈÆäÉæ¼°Ò»ÖÖÖÐ×ÓÖ¯¹¹²âÊÔÉ豸¡£ ±³¾°¼¼Êõ£ºÖ¯¹¹ÊǶྦྷ²ÄÁÏÔÚÉú³É¡¢ÖƱ¸¡¢ºÏ³É¼°¼Ó¹¤µÈ¹¤ÒÕ¹ý³ÌÖÐÐγɵÄÔñÓÅÈ¡Ïò¡£Ä¿Ç°Ö¯¹¹µÄ²â¶¨Ö÷ÒªÒÀ¿¿XÉäÏßÑÜÉä¡¢ÖÐ×ÓÑÜÉä¡¢µç×Ó±³É¢ÉäÑÜÉä
  • רÀûÃû³Æ£º×ÔɨÃè¹âµç¶þ¼«¹ÜÁÐÕ󵥯µ¼¤¹â¸ÉÉæ²â³¤ÒǵÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Ϊ³¤¶È²âÁ¿ÒÇÆ÷¡£¼¤¹â¸ÉÉæ²â³¤ÒÇÆ÷ÓÉÓÚËüµÄ²âÁ¿¾«¶È¸ß£¬Ëٶȿ죬²âÁ¿·¶Î§´ó£¬ÊÊÓÃÐÔ¹ã¶øµÃµ½Ñ¸Ëٵķ¢Õ¹ºÍÓ¦Óá£ÒÔ¼¤¹â¸ÉÉæ¼¼Êõ×öΪ³¤¶È²âÁ¿µÄ·½·¨Ä¿Ç°Ö÷ÒªÓÐÁ½À࣬һÀàÊÇÓõ¥ÆµÎÈ
  • רÀûÃû³Æ£ºÒ»ÖÖÒì²½´®ÐÐ×ÜÏßÐźŵĽâÂëÓë´¥·¢·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°Ò»ÖÖ²âÁ¿ÒÇÆ÷ÖÐÒì²½´®ÐÐ×ÜÏßÐźŵĽâÂëÓë´¥·¢·½·¨£¬ÓÈÆäÉæ¼°Êý×Öʾ²¨Æ÷ÖÐÒì²½´®ÐÐ×ÜÏßÐźŵĽâÂëÓë´¥·¢¡£±³¾°¼¼Êõ£ºÒì²½´®ÐÐ×ÜÏ߹㷺ÔËÓÃÓÚ½ü¾àÀëÉ豸֮¼äµÄ´®ÐÐͨÐÅ£¬Ç¶ÈëʽϵͳµÄµ÷ÊÔ¶Ë
  • רÀûÃû³Æ£ºÊµÊ±ÊóÃܶÈÖÇÄÜÕì²âÒǼ°ÆäϵͳµÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÉæ¼°Ò»ÖÖ̽²âÊóÃܶȵÄ×°Öã¬ÓÈÆäÉæ¼°Ò»ÖÖÀûÓÃRFIDÎÞÏßÊý¾Ý´«Êä¼¼Êõ̽²âÊóÃܶȵÄ×°Öᣱ³¾°¼¼Êõ£ºÊóÀàÊÇËĺ¦Ö®Ò»£¬²»½öÄܹ»´«²¥¶àÖÖ¼²²¡£¬ÇÒͨ¹ýÄöÒ§¡¢µÁʳ¡¢ÎÛȾµÈ·½Ê½¸ø¹¤Òµ¡¢Å©ÄÁ
ɽ¶«ÑÇÐÇÓÎÏ·¹ÙÍø»ú´²ÓÐÏÞ¹«Ë¾
È«¹ú·þÎñÈÈÏߣº13062023238
µç»°£º13062023238
µØÖ·£ºëøÖÝÊÐÁúȪ¹¤ÒµÔ°68ºÅ
¹Ø¼ü´Ê£ºÏ³´²£¬Êý¿ØÏ³´²£¬ÁúÃÅϳ´²
¹«Ë¾¶þάÂë
Copyright 2010-2024 °æÈ¨ËùÓÐ All rights reserved ³ICP±¸19044495ºÅ-12
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿